This study will ultimately aim at providing the scientific community with patient-reported health status data that will contribute facilitate decision-makings. Short- and long-term HRQoL and symptoms will be evaluated in a longitudinal fashion over time to improve the understanding of the impact of the disease and CAR-T cell therapy on patients-wellbeing, symptom burden and daily functioning. This study will capture useful information on the impact of treatment toxicity, the burden of procedures on HRQoL outcomes. The planned collection of PRO and physician-reported adverse events ad early time point will help to compare and integrate these two points of view in healthcare assessment.
Quality of life assessment
Study Type
OBSERVATIONAL
Enrollment
170
Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia
Bologna, Italy
Asst Degli Spedali Civili Di Brescia - Ssvd Centro Trapianti Midollo Per Adulti - Cattedra Di Ematologia
Brescia, Italy
AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale
Florence, Italy
Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti
Genova, Italy
Fondazione Irccs "Istituto Nazionale Tumori" - Milano - Sc Ematologia
Milan, Italy
Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Ad Indirizzo Oncologico
Palermo, Italy
Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica
Pescara, Italy
Aou Pisana - Uo Ematologia Universitaria
Pisa, Italy
Aou Policlinico Umberto I - Dipartimento Di Medicina Traslazionale - Sezione Ematologia
Roma, Italy
Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia
Rozzano, Italy
...and 3 more locations
The proportion of patients with a clinically meaningful improvement in the fatigue score of the PROMIS- Fatigue questionnaire
To assess the proportion of patients with a clinically meaningful improvement in the fatigue score of the PROMIS- Fatigue questionnaire
Time frame: at 12 months
The proportion of patients with a clinically meaningful improvement in the scales of the EORTC QLQ-C30 questionnaire
To assess the proportion of patients with a clinically meaningful improvement in the scales of the EORTC QLQ-C30 questionnaire
Time frame: at 12 months
The time to improvement in the PROMIS-Fatigue score
To assess the time to improvement in the PROMIS-Fatigue score
Time frame: After 2 years from date of registration
The time to improvement in the EORTC QLQ-C30 questionnaires
To assess the time to improvement in the EORTC QLQ-C30 questionnaires
Time frame: After 2 years from date of registration
The time to improvement in the QLQ-NHL-HG29 questionnaires
To assess the time to improvement in the QLQ-NHL-HG29 questionnaires
Time frame: After 2 years from date of registration
The trajectories over time (up to 24 months) of the mean scores from the PROMIS-Fatigue questionnaire.
To estimate the trajectories over time (up to 24 months) of the mean scores from the PROMIS-Fatigue questionnaire.
Time frame: After 2 years from date of registration
The trajectories over time (up to 24 months) of the mean scores from the EORTC QLQ-C30 questionnaire.
To estimate the trajectories over time (up to 24 months) of the mean scores from the EORTC QLQ-C30 questionnaire.
Time frame: After 2 years from date of registration
The trajectories over time (up to 24 months) of the mean scores from the EORTC QLQ-NHL-HG29 questionnaire.
To estimate the trajectories over time (up to 24 months) of the mean scores from the EORTC QLQ-NHL-HG29 questionnaire.
Time frame: After 2 years from date of registration
Short-term (ie., day+10) patient-reported symptomatic toxicities by a core set of items from the PRO-CTCAE Item Library, and comparing them with those reported by the treating physicians.
To assess short-term (ie., day+10) patient-reported symptomatic toxicities by a core set of items from the PRO-CTCAE Item Library, and comparing them with those reported by the treating physicians
Time frame: After + 10 day for infusion
The impact of CAR-T cell therapy on cognitive impairment as measured by the PROMIS Cognitive Function short form 8a questionnaire.
To investigate the impact of CAR-T cell therapy on cognitive impairment as measured by the PROMIS Cognitive Function short form 8a questionnaire.
Time frame: After 2 years from date of registration
The long-term HRQoL and fatigue profile of patients with that of their peers from the general population, using the PROMIS-Fatigue questionnaire.
To compare the long-term HRQoL and fatigue profile of patients with that of their peers from the general population, using the PROMIS-Fatigue questionnaire.
Time frame: After 12 and 24 months from date of registration
The long-term HRQoL and fatigue profile of patients with that of their peers from the general population, using the EORTC QLQ-C30 questionnaire.
To compare the long-term HRQoL and fatigue profile of patients with that of their peers from the general population, using the EORTC QLQ-C30 questionnaire.
Time frame: After 12 and 24 months from date of registration
Factors predicting response to therapy and survival outcomes
To identify pretreatment factors predicting response to therapy and survival outcomes.
Time frame: After 2 years from date of registration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.